share_log

Tharimmune | 10-Q: Q2 2024 Earnings Report

Tharimmune | 10-Q: Q2 2024 Earnings Report

Tharimmune | 10-Q：2024财年二季报
美股SEC公告 ·  08/09 15:12

Moomoo AI 已提取核心信息

Tharimmune, a clinical-stage biotechnology company, reported its financial performance and business developments for the quarter ended June 30, 2024. The company recorded a net loss of $2,325,057 for the quarter, with a net loss per share of $2.42. This compares to a net loss of $2,336,914 and a net loss per share of $52.06 for the same period in the previous year. The company's total operating expenses for the quarter were $2,373,454, which included research and development costs of $999,553 and general and administrative expenses of $1,373,901. Tharimmune's business development has been marked by the advancement of its therapeutic candidates, including TH104, which has shown positive results in a Phase 1 clinical trial. The company has also entered into significant agreements, such as the Avior License Agreement for the development of TH104 and TH103, and the Enkefalos License Agreement for global rights to cyclotides for delivering HER2 antibodies. Tharimmune's future plans include pursuing a 505(b)(2) approval pathway for TH104, initiating a Phase 2 trial for chronic pruritus in PBC patients, and advancing TH3215 and TH1940 into IND-enabling studies in 2025.
Tharimmune, a clinical-stage biotechnology company, reported its financial performance and business developments for the quarter ended June 30, 2024. The company recorded a net loss of $2,325,057 for the quarter, with a net loss per share of $2.42. This compares to a net loss of $2,336,914 and a net loss per share of $52.06 for the same period in the previous year. The company's total operating expenses for the quarter were $2,373,454, which included research and development costs of $999,553 and general and administrative expenses of $1,373,901. Tharimmune's business development has been marked by the advancement of its therapeutic candidates, including TH104, which has shown positive results in a Phase 1 clinical trial. The company has also entered into significant agreements, such as the Avior License Agreement for the development of TH104 and TH103, and the Enkefalos License Agreement for global rights to cyclotides for delivering HER2 antibodies. Tharimmune's future plans include pursuing a 505(b)(2) approval pathway for TH104, initiating a Phase 2 trial for chronic pruritus in PBC patients, and advancing TH3215 and TH1940 into IND-enabling studies in 2025.
临床生物技术公司Tharimmune公布了截至2024年6月30日的财务业绩和业务发展情况。该公司本季度录得净亏损2325057美元，每股净亏损2.42美元。相较于同期去年的净亏损2336914美元和每股净亏损52.06美元，有所好转。本季度该公司的总营业费用为2373454美元，其中包括999553美元的研究和开发成本和1373901美元的一般和管理费用。Tharimmune的业务发展已经取得进展，其中包括TH104在一期临床试验中取得了积极的结果。该公司还进入了重大协议，如Avior许可协议，用于开发TH104和TH103，以及Enkefalos 许可协议，用于全球范围内 HER2抗体给药的环状肽的权利。Tharimmune的未来计划包括追求TH104的505（b）（2）批准途径，启动PBC患者慢性瘙痒的二期试验，并在2025年推进TH3215 和TH1940进入IND-enabling 研究。
临床生物技术公司Tharimmune公布了截至2024年6月30日的财务业绩和业务发展情况。该公司本季度录得净亏损2325057美元，每股净亏损2.42美元。相较于同期去年的净亏损2336914美元和每股净亏损52.06美元，有所好转。本季度该公司的总营业费用为2373454美元，其中包括999553美元的研究和开发成本和1373901美元的一般和管理费用。Tharimmune的业务发展已经取得进展，其中包括TH104在一期临床试验中取得了积极的结果。该公司还进入了重大协议，如Avior许可协议，用于开发TH104和TH103，以及Enkefalos 许可协议，用于全球范围内 HER2抗体给药的环状肽的权利。Tharimmune的未来计划包括追求TH104的505（b）（2）批准途径，启动PBC患者慢性瘙痒的二期试验，并在2025年推进TH3215 和TH1940进入IND-enabling 研究。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间